Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial
Ly‐Mee Yu(Dartmouth–Hitchcock Medical Center), Richard Hobbs(University of Oxford), Monique Andersson(John Radcliffe Hospital), Philip Evans(University of Exeter), Dan V. Nicolau(Queensland University of Technology), Mona Bafadhel(National Institute for Health and Care Research), Oghenekome Gbinigie(University of Oxford), Sanjay Ramakrishnan(Oxford BioMedica (United Kingdom)), Gail Hayward(University of Oxford), Peter J. Barnes(Imperial College London), Milensu Shanyinde(University of Oxford), Emma Ogburn(University of Oxford), Mark Fitzgerald(Berry & Associates (United States)), Duncan Richards(University of Oxford), Richard Russell(Southern Health NHS Foundation Trust), Oliver van Hecke(University of Oxford), Mahendra Patel(University of Oxford), Benjamin R. Saville(Vanderbilt University), Michelle A. Detry(Berry & Associates (United States)), Nicholas Berry(Berry & Associates (United States)), Richard EK Russell(The University of Queensland), Christina Saunders(Berry & Associates (United States)), Nicholas Thomas(National Institute for Health and Care Excellence), Christopher Butler(University of Oxford), Jienchi Dorward(Centre for the AIDS Programme of Research in South Africa), Simon de Lusignan(University of Oxford), Victoria Harris(University of Oxford)
Cited by 310
Related Papers
ESC Guidelines for the management of grown-up congenital heart disease (new version 2010): The Task Force on the Management of Grown-up Congenital Heart Disease of the European Society of Cardiology (ESC)
|European Heart Journal|2010|2.3k
The cytokine network in asthma and chronic obstructive pulmonary disease
|Journal of Clinical Investigation|2008|968
Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab As Initial Therapy for Chronic Lymphocytic Leukemia
|Journal of Clinical Oncology|2005|951
Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19
|JAMA|2020|884
Outcomes for COPD pharmacological trials: from lung function to biomarkers
|European Respiratory Journal|2008|856